Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed) (349026)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Next deadline: Feb 16, 2024

Later deadlines: Mar 16, 2024, Jun 16, 2024, Jul 16, 2024, Oct 16, 2024, Nov 16, 2024, Feb 16, 2025, Mar 16, 2025, Jun 16, 2025, Jul 16, 2025, Oct 16, 2025, Nov 16, 2025, Feb 16, 2026, Mar 16, 2026, Jun 16, 2026, Jul 16, 2026

Grant amount: Up to US $275,000

Funding uses: Research

Location of project: Anywhere in the world

Location of residency: Anywhere in the world

Overview:

NOTE: The following deadlines apply to standard grant applications (due by 5:00 pm  local time of applicant organization):

• October 16, 2023
• February 16, 2024
• June 16, 2024
• October 16, 2024
• February 16, 2025
• June 16 , 2025
• October 16, 2025
• February 16, 2026
• June 16, 2026

The following deadlines apply to Renewal/Resubmission/Revision grant applications (due by 5:00 pm local time of applicant organization): 

• November 16, 2023
• March 16, 2024
• July 16, 2024
• November 16, 2024
• March 16, 2025
• July 16 , 2025
• November 16, 2025
• March 16, 2026
• July 16, 2026

This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term complex can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to model disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present announcement seeks R21 applications for high risk or early stage exploratory research.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.